GEFTINAT 250 MG

About

GEFTINAT 250 MG, containing Gefitinib, is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It selectively targets the EGFR pathway, which is frequently overactive in certain types of cancer, particularly non-small cell lung cancer (NSCLC). By inhibiting the tyrosine kinase activity of EGFR, Gefitinib blocks the downstream signaling pathways involved in cell proliferation, survival, angiogenesis, and metastasis. This targeted approach makes it an effective treatment option for patients with locally advanced or metastatic NSCLC who have activating EGFR mutations, as identified by a validated test.

Gefitinib's mechanism of action allows for a more personalized approach to cancer therapy, focusing on the specific genetic drivers of the tumor. This often results in better response rates and improved progression-free survival compared to traditional chemotherapy in the selected patient population. While generally well-tolerated, careful monitoring for potential side effects, especially dermatological and gastrointestinal issues, is important. The rare but serious risk of interstitial lung disease also necessitates vigilance for respiratory symptoms.

Uses

• Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
• Indicated for patients with activating EGFR mutations.
• Used as a first-line therapy in appropriate patients.
• May be used in patients who have progressed on platinum-based chemotherapy.

Directions For Use

Take orally once daily, with or without food. Swallow the tablet whole.

Benefits

• Targeted therapy for EGFR-mutated NSCLC.
• Significantly improves progression-free survival.
• Convenient oral administration.
• Generally well-tolerated compared to chemotherapy.
• Reduces tumor size and disease progression.
• Improves quality of life for eligible patients.

Side Effects

• Diarrhea
• Skin rash (acneiform)
• Dry skin
• Nausea
• Vomiting
• Stomatitis (mouth sores)
• Elevated liver enzymes
• Interstitial lung disease (rare but serious)
• Conjunctivitis
• Asthenia (weakness)
• Anorexia (loss of appetite)
• Pruritus (itching)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to the potential for increased liver toxicity and gastrointestinal irritation while on this medication.
• Pregnancy - Not recommended during pregnancy as it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a period after.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Gefitinib is excreted in breast milk, posing a potential risk of serious adverse effects to the infant.
• Liver - Use with caution in patients with liver impairment. Liver function should be monitored closely, and dose adjustments may be necessary in severe cases.
• Kidney - Use with caution in patients with kidney impairment. Renal function should be monitored, though no specific dose adjustment guidelines exist for renal impairment.
• Lung - Risk of interstitial lung disease (ILD). Monitor for acute onset or worsening of respiratory symptoms such as shortness of breath, cough, or fever.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.